Fresh analysis reveals that individuals who come off new weight-loss injections like Wegovy and Mounjaro can put back on lost weight far faster than those who stop conventional lifestyle programs.
Research printed in a major health publication demonstrates that while obese people often shed substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these medications need to be informed of the risk of rapid weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight in about one and a half years.
Analyzing Treatments
The analysis, which examined dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
The team note that individuals who shed pounds through diet and exercise typically have a slower weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the way of the jabs explains the heightened regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is no longer kept in check, making binge eating a significant risk."
A Lifelong Disease?
The NHS advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals contend that, due to the high risk of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who note that the findings "highlight the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Experiences
People who have discontinued the medication describe a intense resurgence of appetite.
"It felt as if a trigger flipping and you become starving," described one woman.
The struggle is compounded if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Growing Interest
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is greater among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on combined behavioural support.
